Increased Transcriptional Activity of the CYP3A4* 1B Promoter Variant

Environmental and Molecular Mutagenesis

Volumn 42, Issue 4, 2003, Pages 299-305

  Amirimani, B ^a   Ning, B ^b   Deitz, A C ^a   Weber, B L ^a   Kadlubar, F F ^b   Rebbeck, Timothy R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

CYP3A4; Expression; Human hepatocytes; Polymorphism; Promoter

Indexed keywords

CYTOCHROME P450 3A4; LUCIFERASE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CHILD; CONTROLLED STUDY; DNA FLANKING REGION; ENZYME ACTIVITY; ENZYME BINDING; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE SEQUENCE; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN GENOME; MALE; PHENOTYPE; PROMOTER REGION; REPORTER GENE; REPRESSOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION SITE; WILD TYPE;

BETA-GALACTOSIDASE; CELL LINE; CELL LINE, TUMOR; CELL NUCLEUS; CYTOCHROME P-450 ENZYME SYSTEM; GENES, REPORTER; GENETIC VECTORS; GENOME, HUMAN; HEPATOCYTES; HUMANS; LUCIFERASES; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); TRANSCRIPTION, GENETIC; TRANSFECTION;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0347359079     PISSN: 08936692     EISSN: None     Source Type: Journal    
DOI: 10.1002/em.10199     Document Type: Article

References (27)

1. Amirimani B, Walker AH, Weber BL, Rebbeck TR. 1999. Response: re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 91:1588-1590.
2. Ando Y, Tateishi T, Sekido Y, Yamamoto T, Satoh T, Hasegawa Y. 1999. Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 91:1587-1590.
3. Ball SE, Scatina J, Kao J, Ferron GM, Fruncillo R, Mayer P. 1999. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther 66:288-294.
4. Bertz RJ, Granneman GR. 1997. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258.
5. Deitz AC, Doll MA, Hein DW 1997, A restriction fragment length polymorphism assay that differentiates human N-acetyltransferase-1 (NATI) alleles. Anal Biochem 15:253:219-224.
6. Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, Cheung NK. 1998. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 95:13176-13181.
7. Floyd MD, Gervasini G, Masica AL Jr, Bhat K, Kim RB, Wilkinson GR. 2003. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13:595-606.
8. Gonzalez FJ, Idle JR. 1994. Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clin Pharmacokinet 26:59-70.
9. Goodwin B, Hodgson E, Liddle C. 1999. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 56: 1329-1339.
10. Guengerich FP. 1990. Characterization of the roles of the human cytochrome P450 enzymes in carcinogen metabolism, Asia Pacific J Pharmacol 5:327-345.
11. Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa, S, Itoh S. 1993. Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur J Biochem 218:585-595.
12. Kadlubar FF, Berkowitz GS, Delongchamp RR, Green BL, Wang C, Wolff MS. 2002. The putative high activity variant, CYP3A4* 1B, predicts the onset of puberty in young girls. Cancer Epidemiol Biomarkers Prev 12:327-331.
13. Kocarek TA, Schuetz EG, Strom SC, Fisher RA, Guzelian PS. 1995. Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. Drug Metab Dispos 23:415-421.
14. Lai J, Vesprini D, Chu W, Jemstrom H, Narod SA. 2001. CYP gene polymorphisms and early menarche. Mol Genet Metab 74:449-457.
15. Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, Zhang J, Schuetz EG 2002. Common allelic variants in cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12:121-132.
16. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. 1998. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102:1016-1023.
17. Paris PL, Kupelian PA, Hall JM, Klein EA, Catalona WJ, Casey G. 1999. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 8:901-905.
18. Pichard L, Fabre I, Daujat M, Domergue J, Joyeux H, Maurel P. 1992. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol 41:1047-1055.
19. Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H. 1995. Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol 47:410-418.
20. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. 1998. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 90:1225-1229.
21. Sano M, Ohyama A, Takase K, Yamamoto M, Machida M. 2001. Electrophoretic mobility shift scanning using an automated infrared DNA sequencer. Biotechniques 31:1056-1062.
22. Schuetz EG, Schuetz JD, Strom SC, Thompson MT, Fisher RA, Molowa DT, Li D, Guzelian PS. 1993. Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes. Hepatology 18:1254-1262.
23. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
24. Spurdle AB, Goodwin B, Hodgson E, Hopper JL, Chen X, Purdie DM, McCredie MR, Giles GG, Chenevix-Trench G, Liddle C. 2002. The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 12:355-366.
25. Walker AH, Jaffe JM, Gunasegaram S, Cummings SA, Huang SC, Chern HD, Rebbeck TR. 1998. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Hum Mutat 12:289.
26. Watkins PB. 1992. Drug metabolism by cytochromes P450 in the liver and small bowel Gastroenterol Clin North Am 21:511-526.
27. Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. 1999. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun 259:201-205.